Marsha Budhan
Physician Assistant · Inglewood, CANPI 1174880793
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,376 of the $3,761 with a category attached, or 89.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,731, 9.0 times the $192 reported in 2021. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$327
- Pfizer$326
- Novartis$242
- Bristol Myers Squibb$204
- Sun Pharmaceutical Industries Inc.$199
- Seagen Inc.$199
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,37690%
- Education$38410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 16 | $327 |
| Pfizer | 18 | $326 |
| Novartis | 9 | $242 |
| Bristol Myers Squibb | 12 | $204 |
| Sun Pharmaceutical Industries Inc. | 7 | $199 |
| Seagen Inc. | 2 | $199 |
| Genentech USA, Inc. | 9 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $195 |
| AstraZeneca(2 entities) | 8 | $174 |
| Gilead | 5 | $140 |
| Array Biopharma Inc | 6 | $138 |
| Johnson & Johnson | 2 | $119 |
| Merck | 5 | $112 |
| Daiichi Sankyo Inc. | 4 | $108 |
| Incyte Corporation | 4 | $108 |
| Global Blood Therapeutics, Inc. | 4 | $88 |
| Boehringer Ingelheim | 2 | $74 |
| Sobi, Inc | 3 | $67 |
| Astellas Pharma US Inc | 3 | $67 |
| Eisai Inc. | 3 | $59 |
| Stemline Therapeutics Inc. | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| GSK | 2 | $47 |
| Bayer | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Redhill Biopharma Inc. | 1 | $37 |
| Genmab U.S., Inc. | 1 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Karyopharm Therapeutics Inc. | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Beigene USA, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| AbbVie | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Novocure Inc. | 1 | $15 |
| Spectrum Pharmaceuticals Inc. | 1 | $15 |
How this compares
$3,761 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeytrudaPembrolizumab | 35 | $393,688 |
| OpdivoNivolumab | 23 | $206,574 |
| YervoyIpilimumab | 14 | $113,604 |
| Pemetrexed Disodium | 12 | $13,512 |
| EliquisApixaban | 15 | $11,963 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $593 |
| Letrozole | 28 | $451 |
| Fluconazole | 13 | $407 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $390 |
| Amlodipine Besylate | 60 | $358 |
| Levothyroxine Sodium | 31 | $355 |
| Ibuprofen | 30 | $268 |
| Omeprazole | 19 | $232 |
| Atorvastatin Calcium | 32 | $208 |
| Hydralazine Hcl | 25 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $112 | $393,68835 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo, Yervoy | $327 | $320,17737 claims |
| PfizerEliquis | $326 | $11,96315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Inglewood
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
- Asma HussainiThousand Oaks$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.